Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Johnson & Johnson's Prospects in 2014
Motley Fool
Monday, January 27, 2014 - 9:15am
tags:
JNJ
What Are AstraZeneca plc’s Dividend Prospects Like Beyond 2014?
Motley Fool
Monday, January 27, 2014 - 9:14am
tags:
AstraZeneca, dividends
Novartis: Running Fast to Stand Still?
Motley Fool
Monday, January 27, 2014 - 9:11am
tags:
Novartis, acute heart failure, serelaxin
Did Roche's Press Release Jeopardize The Ongoing Clinical Trials For Its Schizophrenia Drug, Bitopertin?
Forbes
Monday, January 27, 2014 - 8:59am
tags:
schizophrenia, Roche, clinical trials, bitopertin
Pfizer cancer drug fails in 2 late-stage studies, results from 3rd trial expected in 2015
Yahoo/AP
Monday, January 27, 2014 - 8:54am
tags:
Pfizer, dacomitinib, erlotinib, non-small cell lung cancer
Liver Drug Race: Intercept Pharma Vs. Rivals
Seeking Alpha
Monday, January 27, 2014 - 8:21am
tags:
Intercept Pharma, liver disease, OCA, Conatus Pharmaceuticals, Gilead Sciences, Galectin, NASH, non-alcoholic fatty liver disease
Arena Investors Await Strong Sales Data
Seeking Alpha
Monday, January 27, 2014 - 8:17am
tags:
Arena Pharmaceuticals, Belviq, Eisai, Orexigen, Vivus
Teva Plunge Short-Lived to Bernstein Amid Board Overhaul
Businessweek
Sunday, January 26, 2014 - 11:23am
tags:
Teva Pharmaceuticals
Pfizer Inc. Earnings: Can the Big Pharma Stock Keep Recovering?
Motley Fool
Sunday, January 26, 2014 - 11:20am
tags:
Pfizer, earnings
GlaxoSmithKline's Eperzan Gets Closer to Launch
Motley Fool
Sunday, January 26, 2014 - 10:53am
tags:
GSK, Eperzan, diabetes, type 2 diabetes
This Week in Biotech: Clinical Success, Plus Wheeling and Dealing
Motley Fool
Sunday, January 26, 2014 - 10:46am
tags:
BioDelivery Sciences, Endo Health Solutions, Karyopharm Therapeutics, Repligen, Biomarin, Ariad Pharmaceuticals, Eli Lilly, GSK, Shire
This Biotech Powerhouse Could Land Traders Double-Digit Profits
Yahoo/Street Authority
Sunday, January 26, 2014 - 10:43am
tags:
Biogen Idec
Seattle Genetics Will Exceed And Immunogen Will Meet Market Expectations
Seeking Alpha
Sunday, January 26, 2014 - 10:41am
tags:
Seattle Genetics, Immunogen
Teva’s Laquinimod MS Pill Fails to Win EU Agency Backing
Bloomberg
Saturday, January 25, 2014 - 11:39am
tags:
Teva Pharmaceuticals, MS, multiple sclerosis, Active Biotech, laquinimod
Teva Pharma (TEVA) + Active Biotech (ACTI) = Firmly Committed to NERVENTRA Program
Street Insider
Saturday, January 25, 2014 - 11:34am
tags:
Teva Pharmaceuticals, Active Biotech, Nerventra, laquinimod, MS, multiple sclerosis
Big Pharmas Battle For The Billion-Dollar Melanoma Market
Seeking Alpha
Saturday, January 25, 2014 - 11:20am
tags:
melanoma, Bristol-Myers Squibb, Merck
What You Should Listen for When Biogen Idec Inc. Reports Earnings
Motley Fool
Saturday, January 25, 2014 - 11:16am
tags:
Biogen Idec
Why It Could Pay Off To Look At The Big Picture Of Intercept Pharmaceuticals
Seeking Alpha
Saturday, January 25, 2014 - 11:15am
tags:
Intercept Pharma
Pace of Bristol-Myers' cancer trial spooks investors
Yahoo/Reuters
Saturday, January 25, 2014 - 11:14am
tags:
Bristol-Myers Squibb, nivolumab, lung cancer
Focus On Cancer Immunotherapy Results
Seeking Alpha
Saturday, January 25, 2014 - 10:58am
tags:
cancer immunotherapy, ImmunoCellular Therapeutics, ICT-107, DCVax®-L, Northwest Biotherapeutics

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.